Brief: PharmAla Submits Pre-IND Dossier For Novel MDMA Analog To FDA
02/11/2022 15:44
Nov 2 (Reuters) - Pharmala Biotech Holdings Inc
MDMA.CD :
* PHARMALA SUBMITS PRE-IND DOSSIER FOR NOVEL MDMA ANALOG TO
FDA
Source text for Eikon: ID:nGNX2bBcQ4
Further company coverage: MDMA.CD
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Pharmala Biotech Holdings
See all newsBrief: Pharmala Biotech Holdings Rua Bioscience And Pharmala Biotech Partner To Supply Medicinal Mdma In New Zealand
Brief: PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive US Rights To Ala-002
Brief: Pharmala Biotech Executes Definitive Agreement To Form Special Purpose Vehicle, Restora Neurosciences, For Clinical Development Of Patented Novel Mdxx Molecule Apa-01
Brief: Pharmala Executes Binding Letter Of Intent For Formation Of Special Purpose Vehicle To Develop Patented Novel Mdxx Molecule Apa-01
Brief: PharmALa Signs Supply & Data Agreement With Nautilus Sanctuary For Phase 2 Mdma Clinical Trial Treating Post-Traumatic Stress And Adjustment Disorder In Frontline Healthcare Workers And First Responders